TUESDAY, July 6, 2023 (HealthDay News) — The widely used immunotherapy drug nivolumab (Opdivo) is safer and more effective in treating adults and children with advanced Hodgkin lymphoma than the targeted therapy now used as standard care is, new clinical trial results show. Nivolumab outperformed the drug brentuximab vedotin (Adcetris),Continue Reading